The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis
ConclusionIncreased gadolinium-enhancement independent of a concurrent increase in tumor size on MRI should not be used as a marker of NF1-OPG progression and does not appear to be associated with visual decline or initiation of chemotherapy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 7, 2023 Category: Cancer & Oncology Source Type: research

Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018
ConclusionPatients with a history of prior non-CNS malignancy are at an overall increased risk of developing SPGBM relative to the incidence of developing GBM in the general population. However, the incidence of SPGBM after prior non-CNS malignancy varies by primary tumor location, with some non-CNS malignancies demonstrating either increased or decreased predisposition for SPGBM depending on tumor origin. These findings merit future investigation into whether these relationships represent treatment effects or a previously unknown shared predisposition for glioblastoma and non-CNS malignancy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 4, 2023 Category: Cancer & Oncology Source Type: research

Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
ConclusionOur study identifies the combination of entinostat with olaparib as a new potential therapeutic approach forMYC-driven Group 3  MB. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 3, 2023 Category: Cancer & Oncology Source Type: research

RAI-measured frailty predicts non-home discharge following metastatic brain tumor resection: national inpatient sample analysis of 20,185 patients
ConclusionIncreasing RAI-measured frailty status is significantly associated with increased complication rates, eLOS, NHD, and mortality following MBTR. Preoperative frailty assessment using the RAI may aid in preoperative surgical planning and risk stratification for patient selection. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 3, 2023 Category: Cancer & Oncology Source Type: research

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
ConclusionIn contrast to AVAglio, glioblastoma gene expression subgroups were not associated with a differential OS benefit from first-line bevacizumab in the GLARIUS trial. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 3, 2023 Category: Cancer & Oncology Source Type: research

Supramaximal resection based on en-bloc technique reduces tumor burden and prolongs survival in primary supratentorial lobar glioblastoma
ConclusionsApplying en-bloc technique and achieving SMR, which could reduce tumor burden and did not increase additional complications, both had remarkedly positive effects on clinical outcomes in patients with primary supratentorial lobar glioblastomas. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 2, 2023 Category: Cancer & Oncology Source Type: research

Age and sex disparities in Latin-American adults with gliomas: a systematic review and meta-analysis
ConclusionOur study found mean ages of glioma and glioblastoma were 6 and 10  years lower than those reported in the CBTRUS. Our study suggests disparities in the age and sex distribution of gliomas in Latin America compared to other regions.PROSPERO registration numberCRD42021274423. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 29, 2023 Category: Cancer & Oncology Source Type: research

Treatment outcomes for response-based radiotherapy in children and adolescents with central nervous system germinoma: a prospective study
ConclusionGood prognosis was still achieved after reducing dose and extent of radiation for the patients who achieved complete response (CR) after induction chemotherapy or pathological CR after second-look surgery. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 28, 2023 Category: Cancer & Oncology Source Type: research

Advancing personalized prognosis in atypical and anaplastic meningiomas through interpretable machine learning models
ConclusionWith the continuous growth of neuro-oncology data, ML algorithms act as key tools in predicting survival outcomes for WHO grade II and III meningioma patients. By incorporating these interpretable models into a web application, we can practically utilize them to improve risk evaluation and prognosis for meningioma patients. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 28, 2023 Category: Cancer & Oncology Source Type: research

Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study
ConclusionsSeizure recurrence risk is relatively similar between patients with short-term, medium-term, and long-term seizure freedom after completion of antitumour treatment. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 27, 2023 Category: Cancer & Oncology Source Type: research

Characterizing T-cell dysfunction and exclusion signatures in malignant peripheral nerve sheath tumors reveals susceptibilities to immunotherapy
ConclusionsTranscriptomic analysis of TCD and TCE signatures in MPNST samples reveals that a select subset of patients with MPNSTs may benefit from ICB immunotherapy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 27, 2023 Category: Cancer & Oncology Source Type: research

The impact of opioid administration for post gamma knife radiosurgery frame removal: a prospective quality-improvement study
ConclusionMorphine administration prior to frame removal did not improve pain scores or pain control satisfaction. Absence of efficacy may be related to delayed onset of action, and stronger and faster-acting agents should be explored. Pre-removal pain scores were associated with decreased pain control and overall satisfaction, further identifying earlier and stronger pain treatment as a potential area for improvement. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 25, 2023 Category: Cancer & Oncology Source Type: research

Correction to: MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 22, 2023 Category: Cancer & Oncology Source Type: research

Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity
ConclusionsCombination therapy may improve OS and PFS with acceptable toxicities in patients with rHGG compared to reRT or systemic therapy alone. Particularly, combining bevacizumab with reRT prophylactically reduces radionecrosis.Registration: CRD42022291741. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 21, 2023 Category: Cancer & Oncology Source Type: research

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
ConclusionThe combination of survival and MRI analyses identified a subgroup of CCNU/TMZ-treated patients with features that sets them apart from other patients in the trial: short first PFS despite long PPS and significant increase in mean ADC values upon mRANO-defined progression. The observed pattern is compatible with the features commonly observed in pseudoprogression suggesting mRANO-undetected pseudoprogressions in the CCNU/TMZ arm of CeTeG/NOA-09. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - September 20, 2023 Category: Cancer & Oncology Source Type: research